We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Xarelto Indication in ACS Elusive as FDA Rejects Sponsors’ Third Pitch
Xarelto Indication in ACS Elusive as FDA Rejects Sponsors’ Third Pitch
The FDA has for a third time rejected Janssen and Bayer’s push to have their blockbuster blood-thinner Xarelto approved to treat patients with acute coronary syndrome (ACS).